Navigation Links
3SBio Inc. Schedules Unaudited First Quarter 2012 Results
Date:4/23/2012

SHENYANG, China, April 23, 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaudited first quarter 2012 results on Monday, May 14, 2012 at 8:00am (China Standard Time).

Following the earnings announcement, 3SBio's senior management will host a conference call on Monday, May 14, 2012 8:00pm (China Standard Time), 8:00am (US Eastern)  5:00am (US Pacific) to discuss its unaudited first quarter 2012 results and recent business activity. The conference call may be accessed using the dial-in numbers below:

Conference ID: 73956752

Local dial-in:
China landline: 800-819-0121
China mobile: 400-620-8038
Hong Kong : 852-2475-0994
United States: 718-354-1231

International toll-free dial-in:
Hong Kong:  800930346
United States:  1-866-519-4004
United Kingdom:  080-8234-6646
International toll dial-in: 65 6723 9381

Replay- Conference ID: 73956752
A telephone replay will be available two hours after the call until May 22, 2012 at:
International:  61-2-8235-5000
United States: 1-866-214-5335

WebcastA live webcast of the conference will be available on the investor relations section of 3SBio's website at www.3sbio.com and at http://www.media-server.com/m/p/i9xa65b6.

A replay of the webcast will be available within one hour after the conclusion of the call.

About 3SBio Inc.3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information. Investor ContactsBo Tan

Tom FolinsbeeChief Financial Officer

Director of Investor Relations3SBio Inc.

3SBio Inc.Tel: + 86 24 2581-1820

Tel: + 852 8191-6991ir@3SBio.com

ir@3SBio.com


'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Inc. Announces Results of Annual General Meeting
2. 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
3. 3SBio Announces Investor Conference Schedule
4. 3SBio Announces Partial Conversion of Isotechnika Debenture
5. 3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results
6. 3SBio Announces Conversion of Isotechnika Debenture
7. 3SBio Inc. Announces SFDA Approval of High-Dose EPIAO
8. 3SBio Inc. Schedules Unaudited Second Quarter 2011 Results
9. 3SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results
10. 3SBio Inc. to Hold 2011 Annual General Meeting on September 20, 2011
11. 3SBio Inc. Schedules Unaudited Third Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 30, 2017  Akcea Therapeutics, a subsidiary of Ionis ... a Phase 2b dose-ranging study of AKCEA-APO(a)-L Rx ... goal of the study is to determine the dose ... in a planned Phase 3 cardiovascular outcome study. ... strategic collaboration with Novartis to develop and commercialize drugs ...
(Date:3/29/2017)... March 29, 2017  Bodycad announced today that ... (FDA) 510(k) clearance for its Bodycad Unicompartmental Knee ... personalized orthopaedic restoration. Bodycad is the first Canadian ... reconstruction implant system. Bodycad,s revolutionary ... restoration of the patient,s unique anatomical features and ...
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a ... diagnosis through treatment, today announced that Carmine N. Stengone , ... company at the Needham & Company 16 th Annual Healthcare ... a.m. PDT) at the Westin Grand Central Hotel in ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever ... stuff. The season for grass pollen runs from May to July each year; with the ... victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against ...
(Date:3/29/2017)... ... 29, 2017 , ... Wells Pharmacy Network, a proud A4M ... upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben David, CEO ... leader in the training of physicians, scientists, and members of the public on ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Dr. Angela Cotey, ... orthodontic treatment and accepting new pediatric patients, with or without a referral. Dr. Cotey ... have a better orthodontic outcome and experience. When patients receive early treatment, they may ...
(Date:3/29/2017)... ... March 29, 2017 , ... An ... braces. "The rubber bands used in conjunction with my braces always rubbed against ... design a way to prevent this problem." The O.B.S. was the result of ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... South Hills of Pittsburgh now have easier access to the robotic-assisted total-hip ... Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital ...
Breaking Medicine News(10 mins):